The Evolution of Go-to-Market: Building a Commercial Learning System

Over the last two decades, companies have become better at managing technical uncertainty. Across industries, product development has shifted toward iterative methodologies like Lean Startup, agile development, and design thinking. Companies are no longer strangers to prototypes, MVPs, and pilots. The underlying logic is simple: if something is uncertain, test it early and continuously before making major commitments.

Yet when it comes to go-to-market, many organizations revert to a different logic.

Pricing is set. Channels are selected. Positioning is defined. Sales motions are designed. And most of it is still treated as planning rather than experimentation.

The result is a structural mismatch in how companies manage uncertainty. Technical uncertainty is treated as something to be explored through iteration, while commercial uncertainty is treated as something that can be planned upfront. The implicit logic is that product decisions require learning, while commercialization decisions can be planned with sufficient confidence.

This logic rarely gets challenged. Yet it should be, because it directly influences how much value companies ultimately capture from the products they develop.

Unfortunately, the consequences of this logic usually become visible only after launch, when the first commercial results roll in. Companies discover that customers buy differently than expected, that pricing creates friction, that channels underperform, or that partners matter far more than anticipated. By then, key product, commercial, and organizational decisions are already locked in. The issue is not a lack of learning. It is that learning happens later and more expensively than it should, when the cost of pivoting based on new information is already high.

This way of operating is reinforced by organizational design. Product, marketing, sales, and business development are separated into distinct functions with their own budgets, incentives, and metrics. The separation creates clarity, but it also creates a handover point where responsibility shifts from experimentation to execution. The handover itself is not the problem. In many industries, such as pharmaceuticals, medical devices, chemicals, and biotechnology, it is both necessary and appropriate. The problem is what tends to follow it: a shift from testing assumptions to executing a plan.

At that point, many organizations move from structured experimentation in product development into structured execution in go-to-market. 

What is often missing is a comparable discipline of Commercial Learning—the systematic reduction of uncertainty around how a product reaches the market, creates value, and generates growth. Pricing, channels, positioning, buyer behavior, adoption patterns, retention dynamics, and business models are frequently treated as decisions to be made rather than hypotheses to be tested.

Imagine a product team proposing to launch a product without validating customer needs, testing the concept, or gathering market feedback. Most organizations would reject the idea immediately. Yet many of those same organizations are comfortable launching with largely untested assumptions about pricing, channels, adoption, customer acquisition, or retention. The inconsistency is striking.

This is not an argument against planning, specialization, or handovers. In complex organizations, all three are necessary. Nor is it an argument that go-to-market should always be integrated into product development. In some industries that may be both possible and desirable. In others, it may be impractical or unnecessary.

The real issue lies elsewhere.

Organizations have spent decades investing in Technical R&D. They have methodologies, governance structures, metrics, and review mechanisms designed to reduce uncertainty around desirability and feasibility. Few organizations have built an equivalent capability for Commercial Learning.

What those commercial uncertainties are will vary from product to product. For some, the largest uncertainty may be pricing. For others, it may be customer acquisition, channel effectiveness, retention, partner economics, purchasing triggers, or the viability of a subscription model. The objective is not to create a universal commercialization checklist. It is to identify the commercial assumptions that matter most, prioritize them based on uncertainty and potential impact, and systematically generate evidence before major commercial commitments are made.

Organizations that manage commercial uncertainty well already do this. Before committing to a pricing model, channel strategy, or commercialization approach, they run pilots, test partnerships, analyze competitive dynamics, gather market data, and conduct focused experiments. The objective is not to predict the market perfectly. It is to reduce uncertainty before scaling investments. It is to become a learning organization from one end of the process to the other end.

Reach out if you want to improve go-to-market effectiveness and the commercial returns from new products.

In this sense, commercialization should be managed much like product development. The output of go-to-market activities should not be plans alone. It should be evidence. Evidence that increases confidence in the assumptions that underpin the success of the products.

The question, therefore, is not when go-to-market begins.

The question is whether organizations have built a Commercial R&D capability that is as rigorous as the one they use for Technical R&D.

In markets where customer behavior, channels, and business models are evolving rapidly, this distinction should not be just theoretical. The companies that outperform will not simply be those that build better products. They will be those that learn faster about how to bring those products to market.